INS and Guillain-Barre syndrome: The milder GBS symptoms observed in metformin-treated, compared to insulin/sulphonylurea-treated GBS patients with type 2 diabetes, indicates that pharmacological reversal of AMPK signaling block might be associated with reduced GBS severity.